

Title: “Impact of Praziquantel on Schistosoma mansoni Infection Rates and Associated Factors among Primary School Children”

Journal: Parasitology Research Journal,

Corresponding Author: Assefa Demsash Abebe E-mail: assefademsash@gmail.com

S1. Variable assessment questionnaire

Questionnaire: Socio-demographic and behavioral related factors of the Impact of Praziquantel on Schistosoma mansoni Infection Rates and Associated Factors.

Name of institution _____

Participant’s Code (ID No) _____

Part I: Scio demographic-related questions

| S. No | Variables/question | Categories/values/response | Remark |
|-------|----------------------------|------------------------------|--------|
| 101 | Age | _____ Years | |
| 102 | Sex | 1. Male 2. Female | |
| 103 | Where is your residence | 1. Urban 2. Rural | |
| 104 | Grade level | 1. 1- 4 2. 5- 8 | |
| 105 | Parents educational status | 1. Literate 2. Illiterate | |

Part II: Behavioral characteristics

| S. No | Category Variables/question | Categories/value/ response | Remark |
|-------|----------------------------------|----------------------------|--------|
| 106 | Swimming habit | 1. Yes 2. No | |
| 107 | Washing clothes in the river | 1. Yes 2. No | |
| 108 | Crossing the river with barefoot | 1. Yes 2. No | |

s2. Baseline infection intensity

| Baseline infection intensity of the study participants in Teda, Koladiba, and Maksegnit Towns, Northwest Ethiopia, 2024 | | | | | | | |
|---|----------|-------------------|-----------------|-----------------------|-----------------|----------|----------------|
| Variables | Category | Positive n (%) | Light (<100) | Moderate (100-400) | Heavy (>400) | χ^2 | <i>P</i> value |
| Sex | Male | 37(58.7) | 14(22.2) | 18(28.6) | 5(7.9) | 6.584 | 0.037 |
| | Female | 26(41.3) | 16(25.4) | 5(7.9) | 5(7.9) | | |
| | Total | 63(100) | 30(47.6) | 23(36.5) | 10(15.9) | | |
| Age | 5-9 | 24(38.1) | 15(23.8) | 4(6.3) | 5(7.9) | 6.584 | 0.037 |
| | 10-15 | 39(61.9) | 15(23.8) | 19(30.2) | 5(7.9) | | |
| | Total | 63(100) | 30(47.6) | 23(36.5) | 10(15.9) | | |

S3. Checklist: STROBE checklist for observational study

| | Item No. | Recommendation | Page No |
|------------------------------|----------|--|---------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1-2 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 3-4 |
| Objectives | 3 | State-specific objectives, including any pre-specified hypotheses | 4 |
| Methods | | | |
| Study design | 4 | Present key elements of the study design early in the paper | |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 5 |
| Participants | 6 | Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants | 5 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe the comparability of assessment methods if there is more than one group | 5 |
| Bias | 9 | Describe any efforts to address potential sources of bias | |
| Study size | 10 | Explain how the study size was arrived at | 5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 8 |
| | | (b) Describe any methods used to examine subgroups and interactions | |
| | | (c) Explain how missing data were addressed | 8 |
| | | (d) Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy | |
| | | (e) Describe any sensitivity analyses | |
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | |
| | | (b) Give reasons for non-participation at each stage | 9 |
| | | (c) Consider the use of a flow diagram | |
| Descriptive data | 14* | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | 9 |
| | | (b) Indicate the number of participants with missing data for each variable of interest | |

| | | | |
|-------------------|-----|--|-------|
| Outcome data | 15* | Cross-sectional study—Report numbers of outcome events or summary measures | 9-10 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 9-10 |
| | | (b) Report category boundaries when continuous variables were categorized | |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 10-13 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both the direction and magnitude of any potential bias | 13 |
| Interpretation | 20 | Give a cautious overall interpretation of results, considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 13 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 13 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 14 |